BREAKOUT WATCH

Toronto, Ontario--(Newsfile Corp. - October 4, 2021) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), a progressive medical device technology company and developer of the AcuVid™ Covid-19 Rapid Antigen Saliva Test, provides the following update for its AcuVid^TM Covid-19 Rapid Saliva Antigen Test.

• Therma Bright filed its application for EUA approval to market its AcuVid™ Covid-19 Rapid Antigen Saliva Test with the US FDA on as previously reported on July 22^nd and September 1^st, 2021. Therma continues to monitor and interact with the US FDA as necessary regarding our active submission.

• Therma Bright has ordered sufficient materials and components to manufacture the first batch of AcuVid™ tests in the US. At the same time, Therma is securing multiple manufacturing sites in different countries to be able to meet the anticipated demand for our test in the US and elsewhere.

• Therma is identifying and negotiating with potential customers in various jurisdictions to secure initial orders pending regulatory approval.

• In September the Centers for Disease Control and Prevention (CDC) stated that they expect shortages of rapid tests as demand increases. The CDC, and other bodies, recommend serial testing using rapid antigen tests at least once per week, along with other mitigation measures, such as masking and social distancing, to reduce disease transmission, especially in congregant settings such as workplaces, schools and large events.

• Therma is currently identifying sites to perform trials on the AcuVid™ test for home use applications. The results from these trials will be used to file for approval to market the AcuVid™ Covid-19 Rapid Antigen Saliva Test for home use by non-healthcare professionals. This should greatly expand the market for our test. Once a site is identified, Therma expects to report back to shareholders on the expected date to complete the home use clinical study.

Rob Fia, CEO of Therma Bright, commented, "We continue to build manufacturing capacity for our test in anticipation of approval so that we can meet the expected huge demand for rapid testing. Our saliva-based test is easier to use and less intrusive than nasal swab-based tests and is ideally suited for rapid testing for all subjects."

Therma Bright is not making any express or implied claims that its test product has the ability to eliminate or cure COVID-19 or the SARS-CoV-2 virus.

About Therma Bright Inc.

Therma Bright is a progressive medical device technology company focused on providing consumers and medical professionals with quality medical devices that address their medical and healthcare needs. The Company's initial breakthrough proprietary technology delivers effective, non-invasive and pain-free skincare. Therma Bright received a Class II medical device status from the US FDA in 1997 for its platform technology that is indicated for the relief of the pain, itch, and inflammation of a variety of insect bites or stings.

Therma Bright Inc. trades on the TSXV: THRM, OTCQB: TBRIF, FSE: JNX. For more information visit: www.thermabright.com and www.coldsores.com

Toronto, Ontario--(Newsfile Corp. - September 1, 2021) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, is pleased to provide an update on its AcuVid™ Saliva Test with the US Food & Drug Administration's Emergency Use Authorization (EUA) application.

"During the past 30 days, the Therma Bright team has been actively engaged with officials at the FDA around our first-of-its-kind AcuVid™ COVID-19 Rapid Antigen Saliva Test and our successful clinical study results," expressed Rob Fia, CEO of Therma Bright. "The team, with support from our US development partners, have successfully completed and submitted additional research and documentation requested by the FDA, and we now await for the Administration to complete its review for Emergency Use Authorization."

To date, all the COVID-19 rapid antigen tests that have been FDA-EUA approved are nasal swab tests. The Company expects its saliva-based COVID-19 antigen test to become the first rapid test to receive FDA-EUA approval. As AcuVid™ is an innovative, leading-edge rapid saliva test solution, additional information was required for the FDA-EUA review process.

In addition, the Company has also amended its CE application for the AcuVid™ Saliva Test with the new saliva collection and testing process and has received CE final approval certification from the EU competent authority of Belgium.

The Company also reports that it has received TSXV approval to the debt settlement previously announced August 12, 2021 and has consequently issued 118,750 common shares at a deemed price of $0.40/share. These shares are subject to a hold period expiring January 1, 2022, in accordance with applicable securities laws and the policies of the TSXV.

Therma Bright advises that it has also issued 325,000 warrants to a consultant for services rendered pursuant to a securities for services agreement previously announced April 22, 2021. Each warrant entitles the consultant to purchase one common share for two years at a price of $0.41. All of these securities are subject to a hold period expiring January 1, 2022, in accordance with applicable securities laws and the policies of the TSXV.

The Company has also agreed to issue 200,000 bonus shares in relation to the execution of an agreement relating to the sale and distribution of antibody testing kits. Based on the Company's current market price, these shares will be issued at a deemed price of $0.36/share. The issuance of these bonus shares is subject to approval from the TSXV.

Therma Bright is not making any express or implied claims that its test product has the ability to eliminate or cure COVID-19 or the SARS-CoV-2 virus.

About Therma Bright Inc.

Therma Bright, developer of the AcuVid™ COVID-19 Rapid Antigen Saliva Test, is a progressive medical diagnostic and device technology company focused on providing consumers and medical professionals with quality, innovative solutions that address some of today's most important medical and healthcare challenges. The Company's initial breakthrough proprietary technology delivers effective, non-invasive and pain-free skincare. Therma Bright received a Class II medical device status from the FDA for its platform technology that is indicated for the relief of the pain, itch, and inflammation of a variety of insect bites or stings. The Company received clearance for the above claims from the US FDA in 1997. Therma Bright Inc. trades on the TSXV (TSXV: THRM) (OTC Pink: TBRIF) (FSE: JNX). Visit: www.thermabright.com.

Provides Update on FDA-EUA Application Process

Toronto, Ontario--(Newsfile Corp. - September 14, 2021) -  Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, announced today its successful up-listing from the OTC Pink Sheets to the OTCQB® Venture Market (the "OTCQB"). Therma Bright will commence trading on the OTCQB with the market open on September 14, 2021, under the symbol "TBRIF".